Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2012;8:7.
Article
Google Scholar
White JF, Bernstein DI. Key pollen allergens in North America. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2003;91:425–35 (quiz 435–6, 492).
Article
Google Scholar
Lok SD, Davis BE, Cockcroft DW. Prevalence of allergen sensitization in 1000 adults in Saskatchewan. Allergy Asthma Clin Immunol. 2017;13:9.
Article
Google Scholar
Ahmed H, Ospina MB, Sideri K, Vliagoftis H. Retrospective analysis of aeroallergen’s sensitization patterns in Edmonton, Canada. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2019;15:6.
Article
Google Scholar
Chan-Yeung M, Anthonisen NR, Becklake MR, Bowie D, Sonia Buist A, Dimich-Ward H, et al. Geographical variations in the prevalence of atopic sensitization in six study sites across Canada. Allergy. 2010;65:1404–13.
Article
CAS
Google Scholar
Couroux P, Ipsen H, Stage BS, Damkjær JT, Steffensen MA, Salapatek AM, et al. A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group. Allergy. 2019;74:361–9.
Article
CAS
Google Scholar
Biedermann T, Winther L, Till SJ, Panzner P, Knulst A, Valovirta E. Birch pollen allergy in Europe. Allergy. 2019;74:1237–48.
CAS
PubMed
Google Scholar
Aerobiology Research Laboratories. Pollen forecasts and collection stations 2020. [Internet]. https://www.pollenexperts.ca/monitoring-network/. Accessed 12 Feb 2020
Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol [Internet]. 2018 [cited 2018 Oct 9];14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156899/
Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:S1-84.
Article
Google Scholar
Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140:950–8.
Article
Google Scholar
Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136:556–68.
Article
Google Scholar
ALK-Abelló A/S. ITULATEKTM (Standardized Allergen Extract, White Birch (Betula Verrucosa)) product monograph. Hørsholm, Denmark. 2020.
Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2011;107:426-431.e1.
Article
Google Scholar
Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016;137:444-451.e8.
Article
CAS
Google Scholar
Bernstein DI, Wanner M, Borish L, Liss GM. The Immunotherapy Committee of the American Academy of Allergy A and I. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol. 2004;113:1129–36.
Article
Google Scholar
Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada (4th edition). 2017;
Blume SW, Yeomans K, Allen-Ramey F, Smith N, Kim H, Lockey RF, et al. Administration and burden of subcutaneous immunotherapy for allergic rhinitis in U.S. and Canadian clinical practice. J Manag Care Spec Pharm. 2015;21:982–90.
PubMed
Google Scholar
Ontario Public Drug Programs [Internet]. http://www.health.gov.on.ca/en/public/programs/drugs/. Accessed 06 Oct 2020
PMPRB. (2019). Dispensing fee policies in public drug plans, 2017/18. [Internet]. http://www.pmprb-cepmb.gc.ca/view.asp?ccid=1308. Accessed 06 Oct 2020
Régie de l’assurance maladie du Québec, RAMQ. (Effective September 30, 2020) [Internet]. http://www.ramq.gouv.qc.ca/en/Pages/home.aspx. Accessed 06 Oct 2020
Dispensing fee Quebec—data on file/personal communication.
Ontario Schedule of Benefits (effective April1, 2020) [Internet]. http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20200306.pdf. Accessed 09 Sep 2020
Medecins Omnipracticiens (June 2020) [Internet]. https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/manuels/syra/medecins-omnipraticiens/100-facturation-omnipraticiens/manuel-omnipraticiens-remuneration-acte-RFP.pdf
2020 full time average hourly rate (Ontario) [Internet]. https://www.livingin-canada.com/salaries-for-registered-nurses.html. Accessed 06 Oct 2020
2018 full time average hourly rate (Montreal-Quebec). Adjusted to 2020. [Internet]. https://www.livingin-canada.com/salaries-for-registered-nurses.html. Accessed 06 Oct 2020
Statistics Canada, average hourly wages employees by selected characteristics and occupation [Internet]. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr69a-eng.htm. Accessed 06 Oct 2020
Government of Canada 2020 Reasonable Allowance Rates [Internet]. https://www.canada.ca/en/revenue-agency/services/tax/businesses/topics/payroll/benefits-allowances/automobile/automobile-motor-vehicle-allowances/reasonable-kilometre-allowance.html. Accessed 06 Oct 2020
Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol. 2014;14:363–70.
Article
CAS
Google Scholar
Sondermann N, Shah-Hosseini K, Henkel K, Schwalfenberg A, Mösges R. Erfolgsfaktoren der Adherence bei Hyposensibilisierung. Allergologie. 2011;34:441–6.
Article
Google Scholar
Damm K, Volk J, Horn A, Allam J-P, Troensegaard-Petersen N, Serup-Hansen N, et al. Patient preferences in allergy immunotherapy (AIT) in Germany - a discrete-choice-experiment. Health Econ Rev. 2016;6:32.
Article
Google Scholar
Ellis AK, Boursiquot J, Carr S, Graham F, Masse M-S. Patient and physician perceptions of seasonal allergic rhinitis and allergen immunotherapy: a parallel physician patient survey. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol [Internet]. 2020 [cited 2020 Nov 19];16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035743/
Biedermann T, Kuna P, Panzner P, Valovirta E, Andersson M, de Blay F, et al. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2019;143:1058-1066.e6.
Article
CAS
Google Scholar
Allam J-P, Andreasen JN, Mette J, Serup-Hansen N, Wüstenberg EG. Comparison of allergy immunotherapy medication persistence with a sublingual immunotherapy tablet versus subcutaneous immunotherapy in Germany. J Allergy Clin Immunol. 2018;141:1898–901.e5.
Article
Google Scholar
Borg M, Løkke A, Hilberg O. Compliance in subcutaneous and sublingual allergen immunotherapy: a nationwide study. Respir Med. 2020;170:106039
Article
Google Scholar
Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol. 2012;2:280–4.
Article
Google Scholar
Björstad Å, Cardell L-O, Hahn-Pedersen J, Svärd M. A cost-minimisation analysis comparing sublingual immunotherapy to subcutaneous immunotherapy for the treatment of house dust mite allergy in a Swedish setting. Clin Drug Investig. 2017;37:541–9.
Article
Google Scholar
Ellis AK, Gagnon R, Hammerby E, Lau A. Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs? Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2019;15:27.
Article
Google Scholar
Rønborg S, Johnsen C, Theilgaard S, Winther A, Hahn-Pedersen J, Andreasen J, et al. Cost-minimisation analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark. J Med Econ. 2016;19:1–17.
Article
Google Scholar